Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07522073 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
A Phase 3 study, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 588
- Enrollment target
NCT07522073: Recruiting Phase 3 study, sponsored by Incyte Corporation.
NCT07522073 is a Phase 3 study that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 588 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (24% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07522073, a Phase 3 study, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 588 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Primary Outcome
Defined as the time from the date of randomization to the date of death due to any cause.
Interventions
- DRUG Placebo
- DRUG INCB161734
- DRUG Investigator's choice of chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 588 participants |
| Start Date | 2026-04-09 |
| Est. Completion | 2029-03-19 |
| Phase | Phase 3 |
What NCT07522073 shows while recruiting
NCT07522073 is an interventional study that assigns participants to a tested intervention. The registered 588 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (24% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07522073 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07522073 about?
NCT07522073 is a clinical study titled "A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma". The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
What is the current status of trial NCT07522073?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 588 participants. The study started on 2026-04-09. Estimated completion is 2029-03-19.
What interventions are being tested in trial NCT07522073?
The interventions under investigation include: Placebo (DRUG), INCB161734 (DRUG), Investigator's choice of chemotherapy (DRUG).
Who is sponsoring clinical trial NCT07522073?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07522073's enrollment target sits among peer trials
588 645th of 2000 higher than 1,356 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06921603 · 588 participants · NA
POCUS-Guided Diuresis for Decompensated Heart Failure
- NCT06986954 · 588 participants
Beacon Tip Sizing Catheter and Slip-Cath Beacon Tip Catheter Study
- NCT01365169 · 590 participants · NA
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
- NCT03774758 · 590 participants
Biomarkers for Risk Stratification in Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI